Novavax, Inc. logo

Novavax, Inc.

NASDAQ:NVAX

Overview | Financials
Company Name Novavax, Inc.
Symbol NVAX
Currency USD
Price 15.4
Market Cap 2,162,221,600
Dividend Yield 0%
52-week-range 3.53 - 23.86
Industry Biotechnology
Sector Healthcare
CEO Mr. John Charles Jacobs M.B.A.
Website https://www.novavax.com

An error occurred while fetching data.

About Novavax, Inc.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu,

Related Stocks

Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc.

ARWR

28.91 USD

Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

29.68 USD

LivaNova PLC logo

LivaNova PLC

LIVN

53.77 USD

Guardant Health, Inc. logo

Guardant Health, Inc.

GH

31.78 USD

Natera, Inc. logo

Natera, Inc.

NTRA

106.1 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

87 USD

Amedisys, Inc. logo

Amedisys, Inc.

AMED

97.58 USD

Cerevel Therapeutics Holdings, Inc. logo

Cerevel Therapeutics Holdings, Inc.

CERE

43.37 USD

CureVac N.V. logo

CureVac N.V.

CVAC

3.6 USD

Financials

Numbers are in millions USD

Numbers are in millions USD